33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Copenhagen, Denmark 15 April 2023 - 18 April 2023

More evidence for remdesivir in severe COVID-19

10 May 2023 by

Treatment with remdesivir reduced mortality in a large cohort of hospitalized patients requiring high-flow oxygen, according to a study presented at ECCMID 2023.

More evidence for remdesivir in severe COVID-19

10 May 2023

Flu can trigger a fatal heart attack

09 May 2023 by

Coming down with influenza – commonly called flu – can increase the risk of having a heart attack by sixfold. This is the takeaway from a replication study presented at ECCMID 2023.

Flu can trigger a fatal heart attack

09 May 2023

COVID-19 long-term sequelae and complications

06 May 2023 by

Long COVID, sometimes referred to as post-acute sequelae of COVID-19, is still highly prevalent despite improved acute treatments, the emergence of newer variants, and wider vaccination coverage, says an expert at ECCMID 2023.

COVID-19 long-term sequelae and complications

06 May 2023

mRNA technology: What do we know?

05 May 2023

The mRNA technology has been researched since the early 60s, with applications not only within the infectious disease space but in rare diseases and respiratory viruses. But the most significant progress has been made during the past decade, said Dr Francesca Ceddia, SVP Respiratory Vaccines, Global Medical, Moderna Inc, at ECCMID 2023.

mRNA technology: What do we know?

05 May 2023

Functional loss common in patients with RSV

05 May 2023 by

For many older adults, functional decline, loss of independence, and ending up in a nursing home is something they dread more than death itself, said Professor Anne Fausley from the University of Rochester School of Medicine, Rochester, New York, US at ECCMID 2023.

Functional loss common in patients with RSV

05 May 2023

Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax

27 Apr 2023 by

The bivalent mRNA-1273.214 booster vaccine provides superior immunogenicity compared with the original COVID-19 mRNA-1273 vaccine in a phase III study, according to an expert who presented at ECCMID 2023.

Bivalent mRNA-1273.214 booster offers superior immunogenicity vs original vax

27 Apr 2023

IV to oral antibiotic switch noninferior to continuous IV in enterobacterales BSI

26 Apr 2023 by

Among patients with enterobacterales bloodstream infection (BSI), switching from intravenous (IV) to oral antibiotics is noninferior to continuous IV antibiotic therapy in reducing treatment failure within 90 days, according to a study presented at ECCMID 2023.

IV to oral antibiotic switch noninferior to continuous IV in enterobacterales BSI

26 Apr 2023

EAGLE trials herald new era for uncomplicated UTI treatment

25 Apr 2023 by

Oral gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action, showed favourable signals for the treatment of uncomplicated urinary tract infections (uUTIs), according to the results of two phase III trials.

EAGLE trials herald new era for uncomplicated UTI treatment

25 Apr 2023

SAFO: No advantage to using two antibiotics to treat MSSA bacteraemia

22 Apr 2023 by

The use of cloxacillin alone is just as good as the combination of cloxacillin plus fosfomycin in terms of achieving treatment success among hospitalized patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia, according to the results of the open-label, phase IV-III SAFO trial presented at the ECCMID 2023.

SAFO: No advantage to using two antibiotics to treat MSSA bacteraemia

22 Apr 2023

Sleep disruption after COVID tied to dyspnoea, other post-acute sequelae

22 Apr 2023 by

Sleep disruption following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness in the CircCOVID cohort sub-study presented at ECCMID 2023.

Sleep disruption after COVID tied to dyspnoea, other post-acute sequelae

22 Apr 2023